CR11762A - Uso del factor liberador de corticotropina para el tratamiento de cancer - Google Patents

Uso del factor liberador de corticotropina para el tratamiento de cancer

Info

Publication number
CR11762A
CR11762A CR11762A CR11762A CR11762A CR 11762 A CR11762 A CR 11762A CR 11762 A CR11762 A CR 11762A CR 11762 A CR11762 A CR 11762A CR 11762 A CR11762 A CR 11762A
Authority
CR
Costa Rica
Prior art keywords
release factor
cancer treatment
corticotropine
corticotropine release
factor
Prior art date
Application number
CR11762A
Other languages
English (en)
Inventor
Freke Stephen Evans
Original Assignee
Neutron Row
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Row filed Critical Neutron Row
Publication of CR11762A publication Critical patent/CR11762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se determina en la presente un método para tratar cáncer en un ser humano administrando una alta dosis del factor de liberación de corticotropina (CRF) durante un periodo de tiempo que excede 3 días
CR11762A 2008-04-30 2010-10-27 Uso del factor liberador de corticotropina para el tratamiento de cancer CR11762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US9480608P 2008-09-05 2008-09-05

Publications (1)

Publication Number Publication Date
CR11762A true CR11762A (es) 2011-04-26

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11762A CR11762A (es) 2008-04-30 2010-10-27 Uso del factor liberador de corticotropina para el tratamiento de cancer

Country Status (17)

Country Link
US (1) US20100113341A1 (es)
EP (1) EP2259793A2 (es)
JP (1) JP2011519375A (es)
KR (1) KR20110021820A (es)
CN (1) CN102036680A (es)
AU (1) AU2009241813A1 (es)
CA (1) CA2722426A1 (es)
CO (1) CO6300959A2 (es)
CR (1) CR11762A (es)
EC (1) ECSP10010631A (es)
IL (1) IL209005A0 (es)
MX (1) MX2010011882A (es)
NI (1) NI201000185A (es)
NZ (1) NZ588877A (es)
RU (1) RU2010148803A (es)
WO (1) WO2009134396A2 (es)
ZA (1) ZA201007729B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
CA2766322A1 (en) * 2009-06-24 2010-12-29 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
US4533654A (en) 1982-09-29 1985-08-06 The Salk Institute For Biological Studies Urotensin peptides
US4528189A (en) 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子－12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
MXPA05012314A (es) * 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
MXPA06014021A (es) * 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
WO2009134396A3 (en) 2010-04-15
EP2259793A2 (en) 2010-12-15
JP2011519375A (ja) 2011-07-07
CA2722426A1 (en) 2009-11-05
AU2009241813A1 (en) 2009-11-05
ECSP10010631A (es) 2011-02-28
KR20110021820A (ko) 2011-03-04
IL209005A0 (en) 2011-01-31
NZ588877A (en) 2012-08-31
WO2009134396A2 (en) 2009-11-05
US20100113341A1 (en) 2010-05-06
CN102036680A (zh) 2011-04-27
RU2010148803A (ru) 2012-06-10
CO6300959A2 (es) 2011-07-21
NI201000185A (es) 2013-04-22
ZA201007729B (en) 2014-02-26
MX2010011882A (es) 2011-02-25

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BRPI0609429B8 (pt) uso de uma solução aquosa com potencial de oxirredução (orp)
MX2020009773A (es) Terapia de combinacion.
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
CY1110341T1 (el) Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας
MX2020001727A (es) Terapia de combinacion.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CR11762A (es) Uso del factor liberador de corticotropina para el tratamiento de cancer
MX2021001764A (es) Terapia de combinacion.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
DK1965801T3 (da) Kombination af azd2171 og pemetrexed
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
AR081024A1 (es) Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
NO20064754L (no) Kombinasjonsterapi
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)